RxDoctor Payments Data

Bret Elliott, MD

Family Medicine · Omaha, NENPI 1902396823

Payments from drug & device makers

$7,166in general payments, 2019–2025

Across 446 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$948
  • Novo Nordisk$846
  • AstraZeneca$546
  • Lilly USA, LLC$522
  • Amgen$337
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,166 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$84,783
Medicare patients
135
Services billed
3,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$39,637
MounjaroTirzepatide37$39,551
EliquisApixaban28$38,141
XareltoRivaroxaban14$23,670
OzempicSemaglutide22$20,938
FarxigaDapagliflozin Propanediol15$12,949
Praluent PenAlirocumab13$6,578
Atorvastatin Calcium234$1,778
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,242
Levothyroxine Sodium178$1,232
Omeprazole98$1,193
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,175
Ipratropium Bromide25$901
Tamsulosin Hcl53$884
Celecoxib28$810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$81$39,63743 claims
Lilly USA, LLCMounjaro$522$39,55137 claims
PfizerEliquis$948$38,14128 claims
Johnson & JohnsonXarelto$215$23,67014 claims
Novo NordiskOzempic$846$20,93822 claims
AstraZenecaFarxiga$546$12,94915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →